244 related articles for article (PubMed ID: 24936872)
21. IDH1 mutations in patients with myelodysplastic syndromes are associated with an unfavorable prognosis.
Thol F; Weissinger EM; Krauter J; Wagner K; Damm F; Wichmann M; Göhring G; Schumann C; Bug G; Ottmann O; Hofmann WK; Schlegelberger B; Ganser A; Heuser M
Haematologica; 2010 Oct; 95(10):1668-74. PubMed ID: 20494930
[TBL] [Abstract][Full Text] [Related]
22. IDH1 and IDH2 mutations in myelodysplastic syndromes and role in disease progression.
DiNardo CD; Jabbour E; Ravandi F; Takahashi K; Daver N; Routbort M; Patel KP; Brandt M; Pierce S; Kantarjian H; Garcia-Manero G
Leukemia; 2016 Apr; 30(4):980-4. PubMed ID: 26228814
[No Abstract] [Full Text] [Related]
23. Prognostic value of U2AF1 mutant in patients with de novo myelodysplastic syndromes: a meta-analysis.
Wang H; Zhang N; Wu X; Zheng X; Ling Y; Gong Y
Ann Hematol; 2019 Dec; 98(12):2629-2639. PubMed ID: 31754743
[TBL] [Abstract][Full Text] [Related]
24. IDH1 and IDH2 mutations confer an adverse effect in patients with acute myeloid leukemia lacking the NPM1 mutation.
Yamaguchi S; Iwanaga E; Tokunaga K; Nanri T; Shimomura T; Suzushima H; Mitsuya H; Asou N
Eur J Haematol; 2014 Jun; 92(6):471-7. PubMed ID: 24443894
[TBL] [Abstract][Full Text] [Related]
25. Prevalence and Clinical Effect of IDH1 and IDH2 Mutations Among Cytogenetically Normal Acute Myeloid Leukemia Patients.
Aref S; Kamel Areida el S; Abdel Aaal MF; Adam OM; El-Ghonemy MS; El-Baiomy MA; Zeid TA
Clin Lymphoma Myeloma Leuk; 2015 Sep; 15(9):550-5. PubMed ID: 26189213
[TBL] [Abstract][Full Text] [Related]
26. In vivo anti-tumor effect of PARP inhibition in IDH1/2 mutant MDS/AML resistant to targeted inhibitors of mutant IDH1/2.
Gbyli R; Song Y; Liu W; Gao Y; Biancon G; Chandhok NS; Wang X; Fu X; Patel A; Sundaram R; Tebaldi T; Mamillapalli P; Zeidan AM; Flavell RA; Prebet T; Bindra RS; Halene S
Leukemia; 2022 May; 36(5):1313-1323. PubMed ID: 35273342
[TBL] [Abstract][Full Text] [Related]
27. Distinct mutation profile and prognostic relevance in patients with hypoplastic myelodysplastic syndromes (h-MDS).
Yao CY; Hou HA; Lin TY; Lin CC; Chou WC; Tseng MH; Chiang YC; Liu MC; Liu CW; Kuo YY; Wu SJ; Liao XW; Lin CT; Ko BS; Chen CY; Hsu SC; Li CC; Huang SY; Yao M; Tang JL; Tsay W; Liu CY; Tien HF
Oncotarget; 2016 Sep; 7(39):63177-63188. PubMed ID: 27527853
[TBL] [Abstract][Full Text] [Related]
28. WHO-defined 'myelodysplastic syndrome with isolated del(5q)' in 88 consecutive patients: survival data, leukemic transformation rates and prevalence of JAK2, MPL and IDH mutations.
Patnaik MM; Lasho TL; Finke CM; Gangat N; Caramazza D; Holtan SG; Pardanani A; Knudson RA; Ketterling RP; Chen D; Hoyer JD; Hanson CA; Tefferi A
Leukemia; 2010 Jul; 24(7):1283-9. PubMed ID: 20485371
[TBL] [Abstract][Full Text] [Related]
29. Mutations in the Spliceosomal Machinery Genes SRSF2, U2AF1, and ZRSR2 and Response to Decitabine in Myelodysplastic Syndrome.
Hong JY; Seo JY; Kim SH; Jung HA; Park S; Kim K; Jung CW; Kim JS; Park JS; Kim HJ; Jang JH
Anticancer Res; 2015 May; 35(5):3081-9. PubMed ID: 25964599
[TBL] [Abstract][Full Text] [Related]
30. Improving Revised International Prognostic Scoring System Pre-Allogeneic Stem Cell Transplantation Does Not Translate Into Better Post-Transplantation Outcomes for Patients with Myelodysplastic Syndromes: A Single-Center Experience.
Alzahrani M; Power M; Abou Mourad Y; Barnett M; Broady R; Forrest D; Gerrie A; Hogge D; Nantel S; Sanford D; Song K; Sutherland H; Toze C; Nevill T; Narayanan S
Biol Blood Marrow Transplant; 2018 Jun; 24(6):1209-1215. PubMed ID: 29474870
[TBL] [Abstract][Full Text] [Related]
31. Isocitrate Dehydrogenase Mutations are Better Prognostic Marker than O6-methylguanine-DNA Methyltransferase Promoter Methylation in Glioblastomas - a Retrospective, Single-centre Molecular Genetics Study of Gliomas.
Houdova Megova M; Drábek J; Dwight Z; Trojanec R; Koudeláková V; Vrbková J; Kalita O; Mlcochova S; Rabcanova M; Hajdúch M
Klin Onkol; 2017; 30(5):361-371. PubMed ID: 29031038
[TBL] [Abstract][Full Text] [Related]
32. Isolated del(5q) in myeloid malignancies: clinicopathologic and molecular features in 143 consecutive patients.
Patnaik MM; Lasho TL; Finke CM; Knudson RA; Ketterling RP; Chen D; Hoyer JD; Hanson CA; Tefferi A
Am J Hematol; 2011 May; 86(5):393-8. PubMed ID: 21523797
[TBL] [Abstract][Full Text] [Related]
33. The clinical implication of SRSF2 mutation in patients with myelodysplastic syndrome and its stability during disease evolution.
Wu SJ; Kuo YY; Hou HA; Li LY; Tseng MH; Huang CF; Lee FY; Liu MC; Liu CW; Lin CT; Chen CY; Chou WC; Yao M; Huang SY; Ko BS; Tang JL; Tsay W; Tien HF
Blood; 2012 Oct; 120(15):3106-11. PubMed ID: 22932795
[TBL] [Abstract][Full Text] [Related]
34. Characteristics, clinical outcome, and prognostic significance of IDH mutations in AML.
DiNardo CD; Ravandi F; Agresta S; Konopleva M; Takahashi K; Kadia T; Routbort M; Patel KP; Mark Brandt ; Pierce S; Garcia-Manero G; Cortes J; Kantarjian H
Am J Hematol; 2015 Aug; 90(8):732-6. PubMed ID: 26016821
[TBL] [Abstract][Full Text] [Related]
35. Effect of enhancer of zeste homolog 2 mutations on the prognosis of patients with myelodysplastic syndrome: A meta-analysis.
Huang X; Wang X
Medicine (Baltimore); 2020 Aug; 99(34):e21900. PubMed ID: 32846854
[TBL] [Abstract][Full Text] [Related]
36. Revised International Prognostic Scoring System (IPSS) predicts survival and leukemic evolution of myelodysplastic syndromes significantly better than IPSS and WHO Prognostic Scoring System: validation by the Gruppo Romano Mielodisplasie Italian Regional Database.
Voso MT; Fenu S; Latagliata R; Buccisano F; Piciocchi A; Aloe-Spiriti MA; Breccia M; Criscuolo M; Andriani A; Mancini S; Niscola P; Naso V; Nobile C; Piccioni AL; D'Andrea M; D'Addosio A; Leone G; Venditti A
J Clin Oncol; 2013 Jul; 31(21):2671-7. PubMed ID: 23796988
[TBL] [Abstract][Full Text] [Related]
37. Epigenetic priming with decitabine followed by low dose idarubicin and cytarabine in acute myeloid leukemia evolving from myelodysplastic syndromes and higher-risk myelodysplastic syndromes: a prospective multicenter single-arm trial.
Zhou X; Mei C; Zhang J; Lu Y; Lan J; Lin S; Zhang Y; Kuang Y; Ren Y; Ma L; Wei J; Ye L; Xu W; Li K; Lu C; Jin J; Tong H
Hematol Oncol; 2020 Oct; 38(4):531-540. PubMed ID: 32469434
[TBL] [Abstract][Full Text] [Related]
38. IDH1/IDH2 mutations define the prognosis and molecular profiles of patients with gliomas: a meta-analysis.
Zou P; Xu H; Chen P; Yan Q; Zhao L; Zhao P; Gu A
PLoS One; 2013; 8(7):e68782. PubMed ID: 23894344
[TBL] [Abstract][Full Text] [Related]
39. Prognostic value of IDH1 mutations identified with PCR-RFLP assay in acute myeloid leukemia patients.
Elsayed GM; Nassar HR; Zaher A; Elnoshokaty EH; Moneer MM
J Egypt Natl Canc Inst; 2014 Mar; 26(1):43-9. PubMed ID: 24565682
[TBL] [Abstract][Full Text] [Related]
40. IPSS-R in 555 Taiwanese patients with primary MDS: Integration of monosomal karyotype can better risk-stratify the patients.
Yang YT; Hou HA; Liu CY; Lin CC; Chou WC; Lee FY; Liu MC; Liu CW; Tang JL; Yao M; Li CC; Kuo YY; Huang SY; Ko BS; Chen CY; Hsu SC; Lin CT; Wu SJ; Tsay W; Chen YC; Tien HF
Am J Hematol; 2014 Sep; 89(9):E142-9. PubMed ID: 24845799
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
